SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW -- Ignore unavailable to you. Want to Upgrade?

To: kathleen who wrote (219)6/24/1998 2:03:00 PM
From: MarcG  Respond to of 857
 
Thanks Kathleen,

Another step in the right direction.

MarcG



To: kathleen who wrote (219)6/28/1998 10:24:00 PM
From: Gerald Underwood  Respond to of 857
 
Kathleen,

Thanks for the link.

I was previously unaware that the UK also was preparing to conduct multi-center trials until I ran across this
info at:
ndirect.co.uk
From the info on this site, apparently S. Africa as well as Belgium are also going to be conducting trials.

Does anyone know how many additional patients the FDA allowed into the latest cost recovery expansion in
the US for Ampligen?

Best,

Gerry


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News